European Primary Care Cardiovascular Society

Primary outcome reduced by anti-inflammatory drug in chronic coronary disease

3' education - Sep. 30, 2020 - Mark Nidorf, MD

Temporarily suspending or continuing ACEi/ARBs in hospitalized patients with COVID-19

3' education - Sep. 30, 2020 - Prof. Renato D. Lopes, MD, PhD

Consideration of BP lowering irrespective of prior CVD or baseline SBP

3' education - Sep. 30, 2020 - Kazem Rahimi, MD

Changes in the 2020 AF guidelines

3' education - Sep. 30, 2020 - Prof. Isabelle van Gelder, MD

All three end points show benefit with another SLGT2 inhibitor in HFrEF

3' education - Sep. 16, 2020 - Milton Packer, MD

SGLT2i provides nephroprotective effects in CKD patients

3' education - Sep. 16, 2020 - Prof. Hiddo Heerspink, PhD

Improved outcomes with early rhythm control in AF

3' education - Sep. 16, 2020 - Prof. Paulus Kirchhof, MD

Proportion of unrecognized MI greater in women

5' education - Aug. 19, 2020 - Yldau van der Ende, MD, PhD

Recovered COVID-19 patients and cardiac abnormalities

3' education - Aug. 19, 2020 - Prof. Rudolf de Boer, MD, PhD

How to detect familial hypercholesterolemia

10' education - July 29, 2020 - Rens Reeskamp, MD

Screening for familial hypercholesterolemia - why and how?

10' education - July 27, 2020 - Prof. Kees Hovingh, MD, PhD

Need for early detection of familial hypercholesterolemia

10' education - July 22, 2020 - Bert Wiegman, MD, PhD

More out-of-hospital cardiac arrest during COVID-19 outbreak in Lombardy, Italy

3' education - June 18, 2020 - Enrico Baldi, MD

Screening for AF, HF and CAD in primary care

5' education - June 16, 2020 - Victor Zwartkruis
Lecture 1 out of 3

COVID-19, ACE2 and RAASi - a scientific perspective

10' education - May 14, 2020 - Prof. Jan Danser, PhD
Lecture 2 out of 3

COVID-19, ACE2 and RAASi - a clinical perspective

10' education - May 14, 2020 - Prof. Murray Epstein, MD
Lecture (panel discussion) 3 out of 3

What are the implications for practice? - A discussion on COVID-19, ACE2 and RAASi

10' education - May 14, 2020 - Profs. John Deanfield, Jan Danser and Murray Epstein

A call to collect data on CV variables in patients with COVID-19

3' education - Apr. 14, 2020 - Prof. Folkert Asselbergs, MD, PhD

Rate of smoking cessation higher with e-cigarettes compared to counseling

3' education - Apr. 13, 2020 - Prof. Mark Eisenberg, MD - ACC 2020

Mechanistic evidence of CV benefit observed with icosapent ethyl

3' education - Apr. 12, 2020 - Prof. Deepak Bhatt, MD - ACC 2020

CV risk factors and biomarkers are similarly associated with incident HF in men and women

Literature - Oct. 22, 2020 - Suthahar N, et al. - J Am Coll Cardiol. 2020

HF biomarkers and CV risk factors were strongly associated with incident HF without any sex-related differences among women and men.

During COVID-19 pandemic in USA, there was a decrease in primary care visits, but increase in telemedicine

Literature - Oct. 13, 2020 - Alexander GC, et al. - JAMA Netw Open. 2020

Changes in the structure of primary care delivery, and differences in content of telemedicine visits vs. office-based visits were observed in the USA during the COVID-19 pandemic.

Primary outcome reduced by anti-inflammatory drug in chronic coronary disease

3' education - Sep. 30, 2020 - Mark Nidorf, MD
Mark Nidorf discusses the results of the LoDoCo2 trial, which evaluated the effects of anti-inflammatory drug colchicine on CV events in patients with coronary artery disease.

ESC 2020 Mark Nidorf discusses the results of the LoDoCo2 trial, which evaluated the effects of the anti-inflammatory drug colchicine on CV events in patients with coronary artery disease.

Temporarily suspending or continuing ACEi/ARBs in hospitalized patients with COVID-19

3' education - Sep. 30, 2020 - Prof. Renato D. Lopes, MD, PhD
BRACE CORONA was a randomized trial that tested two strategies in hospitalized patients with COVID-19 who were on ACEi or ARBs: Temporarily suspending or continuing ACEi/ARBs. Prof. Lopes discusses the results.

ESC 2020 BRACE CORONA was a randomized trial that tested two strategies in hospitalized patients with COVID-19 who were on ACEi or ARBs: Temporarily suspending or continuing ACEi/ARBs. Prof. Lopes discusses the results.

In AF patients at extremes of body weight, Factor Xa inhibitor is efficacious and safe

Literature - Sep. 30, 2020 - Boriani G, et al. - Thromb Haemost 2020

This posthoc analysis of the ENGAGE AF-TIMI 48 trial demonstrated no difference in efficacy and safety of edoxaban vs. warfarin in AF patients with extreme body weight compared to middle body weight.

Increased risk of hypertension with moderate and heavy alcohol consumption

Literature - Sep. 30, 2020 - Mayl JJ et al. - J Am Heart Assoc. 2020

Compared to those who reported no alcohol intake, T2DM patients with moderate (>7 drinks/week) and heavy (>14 drinks/week) consumption had increased risk of elevated BP, hypertension grade I and hypertension grade 2.

Consideration of BP lowering irrespective of prior CVD or baseline SBP

3' education - Sep. 30, 2020 - Kazem Rahimi, MD
BP lowering  of 5 mm Hg results in 10% reduction of major CV events and is consistent whether individuals had a previous CVD or not, and is regardless of baseline SBP.

ESC 2020 A study including 48 RCTs demonstrated that lowering of each 5 mmHg SBP resulted in 10% reduction of major CV events, regardless of baseline SBP and CVD status.

Changes in the 2020 AF guidelines

3' education - Sep. 30, 2020 - Prof. Isabelle van Gelder, MD
During the ESC Congress, the 2020 AF guidelines have been presented. Prof. Van Gelder gives an overview of the most important changes

ESC 2020 During the ESC Congress, the 2020 AF guidelines have been presented. Prof. Van Gelder gives an overview of the most important changes

There is a gap between guidelines and clinical practice for lipid management

Literature - Sep. 30, 2020 - Ray KK, et al. - Eur J Prev Cardiol 2020

Attainment of 2016 guideline-recommended risk-based LDL-c goal was 54% and for 2019 risk-based LDL-c goal this was 33% in patients on lipid-lowering therapy in primary and secondary settings.

In a cohort of pre-diabetes and T2DM patients, the obesity paradox was detected

Literature - Sep. 30, 2020 - Doehner W, et al. - Eur Heart J 2020

Participants who were overweight or obese had lower risk of total and CV mortality in a cohort of prediabetes and T2DM patients from the ORIGIN trial.

Adherence to Mediterranean diet identified by metabolic signature

Literature - Sep. 30, 2020 - Li J et al., - Eur Heart J. 2020

This study identified a metabolic signature, comprising 67 metabolites, that characterizes adherence to a Mediterranean diet and is associated with future CVD risk, independent of traditional risk factors.

All three end points show benefit with another SLGT2 inhibitor in HFrEF

3' education - Sep. 16, 2020 - Milton Packer, MD
Milton Packer shares the results of the EMPEROR-Reduced trial and what these, together with those of DAPA-HF, mean for treatment of HFrEF patients.

ESC 2020 Milton Packer shares the results of the EMPEROR-Reduced trial and what these, together with those of DAPA-HF, mean for treatment of HFrEF patients.